Clinical Trials in Retinitis Pigmentosa Treatment
Weiss, Jeffrey N.
- 出版商: Springer
- 出版日期: 2024-08-21
- 售價: $5,620
- 貴賓價: 9.5 折 $5,339
- 語言: 英文
- 頁數: 276
- 裝訂: Hardcover - also called cloth, retail trade, or trade
- ISBN: 3031587987
- ISBN-13: 9783031587986
無法訂購
商品描述
This book is a compendium of the worldwide ocular stem cell, gene therapy, optogenetic, and other miscellaneous studies treating Retinitis Pigmentosa registered with Clinicaltrials.gov. Clinicaltrials.gov is the largest website listing of registered clinical research studies in the world. The study title and the Clinical Trial Number is provided in order to make it easier for the reader to obtain further information. The book contains chapters that act as an introduction to Retinitis Pigmentosa, as well as discussion and analysis of the studies. References are also included for the readers' use.
Clinical Trials in Retinitis Pigmentosa Treatment is a valuable resource for ophthalmologists, optometrists, other physicians, and researchers.
商品描述(中文翻譯)
《視網膜色素變性臨床試驗治療》是一本匯編了全球在Clinicaltrials.gov註冊的視網膜色素變性幹細胞、基因治療、光遺傳學等相關研究的書籍。Clinicaltrials.gov是全球最大的臨床研究註冊網站。書中提供了研究標題和臨床試驗編號，以方便讀者獲取更多資訊。書中包含了介紹視網膜色素變性的章節，並對這些研究進行了討論和分析。同時也提供了參考文獻供讀者參考。《視網膜色素變性臨床試驗治療》對於眼科醫生、驗光師、其他醫生和研究人員來說是一個寶貴的資源。
作者簡介
Jeffrey N. Weiss, M.D., is the former Chief of Retinal Surgery at the Joslin Diabetes Center in Boston, Faculty of Harvard Medical School, and Visiting Scientist at the Massachusetts Institute of Technology.
Dr. Weiss is the author of more than 100 publications, including 20 books, holds more than 20 U.S. and foreign patents and has been a Reviewer for multiple scholarly journals. He has served as a Visiting Professor, performed surgery, and lectured both nationally and internationally. Dr. Weiss is also the founder of two companies, Ocular Research Associates Inc., and Micron Ophthalmic, Inc., which have manufactured and sold Dr. Weiss' inventions worldwide.
Dr. Weiss was the first to invent the equipment and develop the technique to safely perform retinal vessel cannulation. This surgery remains the only option for patients with severe stroke in the eye. He was also the first to report the use of hyperbaric oxygen treatment tosuccessfully treat dry age-related macular degeneration and longer standing central retinal artery occlusions.
Dr. Weiss performed the first retinal stem cell surgery in 2010, and is the Principal Investigator of The Stem Cell Ophthalmology Treatment Studies I/II, the largest retinal and optic nerve stem cell studies in the world, and The Neurologic Stem Cell Treatment Study. The studies are Institutional Review Board (IRB) approved, registered with NIH, and listed on ClinicalTrials.gov.
作者簡介(中文翻譯)
Jeffrey N. Weiss, M.D. 是波士頓Joslin糖尿病中心視網膜手術前主任、哈佛醫學院教職員，以及麻省理工學院訪問科學家。
Dr. Weiss是超過100篇論文的作者，包括20本書籍，擁有超過20項美國和國外專利，並擔任多個學術期刊的審稿人。他曾擔任訪問教授，進行手術並在國內外演講。Dr. Weiss也是兩家公司的創辦人，分別是Ocular Research Associates Inc.和Micron Ophthalmic, Inc.，這兩家公司在全球製造和銷售Dr. Weiss的發明。
Dr. Weiss是第一個發明安全進行視網膜血管穿刺手術的人，這種手術是眼部嚴重中風患者的唯一選擇。他還是第一個報告使用高壓氧治療成功治療乾性老年黃斑變性和長期中央視網膜動脈阻塞的人。
Dr. Weiss於2010年進行了第一例視網膜幹細胞手術，並擔任「幹細胞眼科治療研究I/II」和「神經幹細胞治療研究」的首席研究員，這是全球最大的視網膜和視神經幹細胞研究。這些研究已獲得機構審查委員會(IRB)批准，並在美國國立衛生研究院(NIH)註冊，並列於ClinicalTrials.gov。
